George Budwell

George Budwell


George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies.

Recent articles

rocket (3)

Why Novavax Stock Is Skyrocketing Today

Novavax lands a massive $1.6 billion award from the federal government's Operation Warp Speed program.


Why Heron Therapeutics Stock Is Tanking Today

Its non-opioid painkiller gets a rejection over non-clinical issues.

fatty liver

Why Intercept Pharmaceuticals Stock Is Crashing Today

Shares are taking a step back after the FDA rejected the company's NASH candidate.


2 Top Healthcare Stocks to Watch in June

Heron Therapeutics and Novavax are two key healthcare stocks to watch this month.


Why Adaptimmune Therapeutics Stock Crushed It in May

The biotech continued its winning ways.

Prescription drugs

2 Top Pharma Stocks to Buy in June

Bristol Myers Squibb and Pfizer are two of the safest stocks investors can buy right now.


Why Agenus Stock Took Flight in May

The immunotherapy company may be a diamond in the rough.

2020 Growth

Why Novavax Stock Is Up Big Yet Again Today

Novavax scores another large grant for its COVID-19 vaccine candidate.

Recovery (2)

Why Minerva Neurosciences Is Heading Higher Today

The biotech's shares are mounting a modest comeback after their ugly decline on Friday.

paper plane concept

Why Adaptimmune Therapeutics Stock Sank and Then Quickly Rebounded Today

Adaptimmune prudently decided to take advantage of its soaring share price to raise capital.


Why Evofem Biosciences Stock Is on Fire Today

Evofem Biosciences scored a major regulatory win last Friday.


Why Novavax Stock Is Skyrocketing Tuesday

Novavax's experimental COVID-19 vaccine has officially entered an early-stage trial.

COVID vaccine

Why Dynavax Technologies Is Jumping Today

Dynavax's COVID-19 vaccine program is turning heads this morning.

high growth (2)

Why Novavax Is Blasting Higher Today

The clinical biotech is benefiting from an analyst upgrade and optimism about its pipeline.

marijuana bush

Why Aurora Cannabis Stock Is Soaring Today

The marijuana specialist's better-than-expected third-quarter 2020 earnings report has investors excited.

biotech researcher

Why Sorrento Therapeutics Stock Is on Fire Today

Sorrento's shares are continuing their surge from last Friday. Here's why.

canopy view

Why Aphria's Stock Crushed It in April

Aphria's shares surged higher last month on the heels of a strong Q3 report.

Female cancer patients

Why Clovis Oncology Stock Marched Higher in April

Clovis Oncology's stock reversed course last month.

Excited kid

Why MyoKardia Stock Is on Fire Today

The company's experimental heart drug hit the mark in a pivotal study.


Why DexCom Stock Rocketed Higher in April

DexCom's shares have been crushing it of late.